ArticlePloS one2017
Evaluation of macrocyclic hydroxyisophthalamide ligands as chelators for zirconium-89.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Preclinical Evaluation of a Radiolabeled Anti-PSMA Dimeric Aptamer in a Murine Model of Human Prostate Cancer.Molecules (Basel, Switzerland) · 2026Article
- The Evaluation of (1Molecules (Basel, Switzerland) · 2025Article
- Click-to-Release: Cleavable Radioimmunoimaging with [Theranostics · 2023Article
- The Race for Hydroxamate-Based Zirconium-89 Chelators.Cancers · 2021Review
- Article
- Polyazamacrocycle Ligands FacilitateInorganic chemistry · 2020Article
- Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* forEuropean journal of nuclear medicine and molecular imaging · 2019Article
- Preparation of Zirconium-89 Solutions for Radiopharmaceutical Purposes: Interrelation Between Formulation, Radiochemical Purity, Stability and Biodistribution.Molecules (Basel, Switzerland) · 2019Article
- Progress of Coordination and Utilization of Zirconium-89 for Positron Emission Tomography (PET) Studies.Nuclear medicine and molecular imaging · 2019Review
- A comprehensively revised strategy that improves the specific activity and long-term stability of clinically relevantDalton transactions (Cambridge, England : 2003) · 2018Article
- Recent Advances in Zirconium-89 Chelator Development.Molecules (Basel, Switzerland) · 2018Review
- Cyclic versus Noncyclic Chelating Scaffold forMolecular pharmaceutics · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The development of bifunctional chelators (BFCs) for zirconium-89 immuno-PET applications is an area of active research. Herein we report the synthesis and evaluation of octadentate hydroxyisophthalamide ligands (1 and 2) as zirconium-89 chelators. While both radiometal complexes could be prepared quantitatively and with excellent specific activity, preparation of 89Zr-1 required elevated temperature and an increased reaction time. 89Zr-1 was more stable than 89Zr-2 when challenged in vitro by excess DTPA or serum proteins and in vivo during acute biodistribution studies. Differences in radiometal complex stability arise from structural changes between the two ligand systems, and suggest further ligand optimization is necessary to enhance 89Zr chelation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.